Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-051/00
A61M-036/14
A61M-036/00
출원번호
UP-0405334
(2006-04-17)
등록번호
US-7632484
(2009-12-24)
발명자
/ 주소
Yang, David J.
Liu, Chun W.
Yu, Dong Fang
Kim, E. Edmund
출원인 / 주소
Board of Regents, The University of Texas System
대리인 / 주소
Fulbright & Jaworski LLP
인용정보
피인용 횟수 :
1인용 특허 :
92
초록▼
The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used
The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.
대표청구항▼
What is claimed is: 1. A reagent for preparing a scintigraphic imaging agent comprising a targeting ligand covalently linked to ethylenedicysteine (EC), wherein the targeting ligand is an anticancer agent that is methotrexate, doxorubicin, tamoxifen, paclitaxel, topotecan, LHRH, mitomycin C, etopos
What is claimed is: 1. A reagent for preparing a scintigraphic imaging agent comprising a targeting ligand covalently linked to ethylenedicysteine (EC), wherein the targeting ligand is an anticancer agent that is methotrexate, doxorubicin, tamoxifen, paclitaxel, topotecan, LHRH, mitomycin C, etoposide tomudex, podophyllotoxin, mitoxantrone, camptothecin, colchicine, endostatin, fludarabin, gemcitabine, or tomudex; an agent that mimics glucose; a folate receptor targeting ligand; or a tumor apoptotic cell targeting ligand or a tumor hypoxia targeting ligand that is annexin V, colchicine, nitroimidazole, mitomycin, or metronidazole. 2. The reagent of claim 1, wherein the targeting ligand is an agent that mimics glucose. 3. The reagent of claim 1, further comprising a linker between said targeting ligand and said ethylenedicysteine (EC). 4. A kit comprising one or more sealed containers, and a predetermined quantity of an ethylenedicysteine (EC)-targeting ligand conjugate composition in one or more of the sealed containers, wherein the targeting ligand is an anticancer agent that is methotrexate, doxorubicin, tamoxifen, paclitaxel, topotecan, LHRH, mitomycin C, etoposide tomudex, podophyllotoxin, mitoxantrone, camptothecin, colchicine, endostatin, fludarabin, gemcitabine, or tomudex; an agent that mimics glucose; a folate receptor targeting ligand; a DNA topoisomerase inhibitor; a tumor apoptotic cell targeting ligand or a tumor hypoxia targeting ligand that is annexin V, colchicine, nitroimidazole, mitomycin, or metronidazole; or glutamate pentapeptide. 5. The kit of claim 4, wherein the kit further comprises a reducing agent. 6. The kit of claim 4, wherein the targeting ligand is paclitaxel. 7. The kit of claim 4, wherein the composition further comprises a linker between said ethylenedicysteine (EC) and said targeting ligand. 8. The kit of claim 5, further defined as comprising a sealed containing comprising a reducing agent. 9. The kit of claim 8, wherein the ethylenedicysteine (EC)-targeting ligand conjugate composition and the reducing agent are comprised together in a sealed container. 10. The kit of claim 7, further defined as comprising a sealed containing comprising a linker. 11. The kit of claim 8, wherein the kit comprises a first sealed containing comprising the ethylenedicysteine (EC)-targeting ligand conjugate composition and a second sealed containing comprising a reducing agent. 12. The kit of claim 4, wherein one or more of the sealed containers is further defined as a bag. 13. The kit of claim 5, wherein the reducing agent is a dithionite ion, a stannous ion or a ferrous ion. 14. The kit of claim 4, wherein the targeting ligand is an anticancer agent that is methotrexate, doxorubicin, tamoxifen, paclitaxel, topotecan, LHRH, mitomycin C, etoposide tomudex, podophyllotoxin, mitoxantrone, camptothecin, colchicine, endostatin, fludarabin, gemcitabine, or tomudex. 15. The kit of claim 14, wherein the anticancer agent is methotrexate. 16. The kit of claim 2, wherein the agent that mimics glucose is deoxyglucose. 17. The kit of claim 2, wherein the agent that mimics glucose is glucosamine. 18. The kit of claim 4, wherein the targeting ligand is a DNA topoisomerase inhibitor. 19. The kit of claim 4, wherein the folate receptor targeting ligand is folate. 20. The kit of claim 4, wherein the folate receptor targeting ligand is tomudex. 21. The kit of claim 4, wherein the targeting ligand is a tumor apoptotic cell targeting ligand or a tumor hypoxia targeting ligand that is annexin V, colchicine, nitroimidazole, mitomycin, or metronidazole. 22. The kit of claim 21, wherein the targeting ligand is nitroimidazole. 23. The kit of claim 4, wherein the components of the kit are in a liquid form, frozen form, or dry form. 24. The kit of claim 4, wherein the components of the kit are in a lyophilized form. 25. The kit of claim 7, wherein the linker is a water soluble peptide, glutamic acid, polyglutamic acid, aspartic acid, polyaspartic acid, bromoethylacetate, ethylenediamine or lysine. 26. The kit of claim 4, wherein the kit further comprises one or more pharmaceutical adjunct materials. 27. The kit of claim 26, wherein the one or more pharmaceutical adjunct materials are selected from the group consisting of a pharmaceutically acceptable salt, a buffer, a preservative, and antioxidant, and a scavenger. 28. The kit of claim 27, wherein the kit comprises an antioxidant. 29. A kit comprising one or more sealed containers, a predetermined quantity of an ethylenedicysteine (EC)-targeting ligand conjugate composition in one or more sealed containers, and vitamin C. 30. The kit of claim 27, wherein the kit comprises a scavenger. 31. The kit of claim 30, wherein the scavenger is glucoheptonate or EDTA. 32. The kit of claim 4, wherein the kit is a home-made kit. 33. A kit comprising one or more sealed containers, a predetermined quantity of ethylenedicysteine (EC)-targeting ligand conjugate composition in one or more sealed containers, SnCl2, Na2IPO4, ascorbic acid, and NaEDTA. 34. The kit of claim 33, wherein the kit comprises lyophilized EC (3 mg), SnCl2 (100 μg), Na2IPO4 (13.5 mg), ascorbic acid (0.5 mg) and NaEDTA (0.5 mg) at pH 10. 35. A kit comprising one or more sealed containers, a predetermined quantity of ethylenedicysteine (EC)-folate in one or more sealed containers, SnCl2, Na2IPO4, ascorbic acid, and NaEDTA. 36. The kit of claim 35, wherein the kit comprises lyophilized residue of EC-folate (3 mg), SnCl2 (100 μg), Na2IPO4 (13.5 mg), ascorbic acid (0.5 mg), and NaEDTA (0.5 mg). 37. A kit comprising one or more sealed containers, a predetermined quantity of ethylenedicysteine (EC)-MN or EC-NIM, SnCI2, Na2IPO4, ascorbic acid, and NaEDTA. 38. The kit of claim 37, wherein the kit comprises lyophilized residue of EC-MN or EC-NIM (3 mg), SnCl2 (100 μg), Na2IPO4 (13.5 mg), ascorbic acid (0.5 mg), and NaEDTA (0.5 mg).
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (92)
Weitl Frederick L. (Martinez CA) Raymond Kenneth N. (Berkeley CA), 2,3-Dihydroxybenzoic acid amides of tetraazaalkanes and tetaaza cycloalkanes.
Torchilin Vladimir P. (41 ; 8th St. ; #3208 Charlestown MA 02129) Trubetskoy Vladimir S. (9 Morton Ter. Milton MA 02186) Wolf Gerald L. (5 Hawthorn Rd. Winchester MA 01890), Amphipathic polychelating compounds and methods of use.
Axworthy Donald B. (Brier WA) Theodore Louis J. (Lynnwood WA) Gustavson Linda M. (Seattle WA) Reno John M. (Brier WA), Biotinidase-resistant biotin-DOTA conjugates.
Bogdanov Alexei A. (Newton MA) Weissleder Ralph (Charlestown MA) Brady Thomas J. (Winchester MA) Callahan Ronald (Boston MA), Blood pool imaging composition and method of its use.
Low Philip Stewart (West Lafayette IN) Horn Mark Alan (Piscataway NJ) Heinstein Peter Frederick (West Lafayette IN), Composition and method for tumor imaging.
Nicolotti Robert A. (Furguson MO) Dean Richard T. (Chesterfield MO), Coupling agents for joining radionuclide metal ions with biologically useful proteins.
Linder Karen (Kingston NJ) Nunn Adrian D. (Ringoes NJ) Nowotnik David P. (Flemington NJ) Ramalingam Kondareddiar (Dayton NJ) DiRocco Richard J. (Allentown NJ) Rumsey William L. (Wyndmoor PA) Pirro Jo, Diagnostic imaging methods using rhenium and technetium complexes containing a hypoxia-localizing moiety.
Bergstein Paul L. (Norwood MA) Cheesman Edward H. (Townsend MA) Watson Alan D. (Andover MA), Ester-substituted diaminedithiols and radiolabeled complexes thereof.
Yang, David J.; Liu, Chun W.; Yu, Dong-Fang; Kim, E. Edmond, Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging.
Killat George R. (Midland MI) Tomalia Donald A. (Midland MI), Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities.
Woodle Martin C. (Menlo Park CA) Martin Francis J. (San Francisco CA) Yau-Young Annie (Los Altos CA) Redemann Carl T. (Walnut Creek CA), Liposomes with enhanced circulation time.
Marzilli Luigi G. ; Lipowska Malgorzata ; Hansen Lory ; Taylor ; Jr. Andrew, Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof.
Marzilli Luigi Gaetano ; Lipowska Malgorzata ; Hansen Lory ; Taylor ; Jr. Andrew, Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof.
Srinivasan Ananthachari (Kirkland WA) Fritzberg Alan R. (Edmonds WA) Jones David S. (Seattle WA), Metal radionuclide chelating compounds for improved chelation kinetics.
Fritzberg Alan R. (Edmonds WA) Kasina Sudhakar (Kirkland WA) Srinivasan Ananthachari (Kirkland WA) Wilbur Daniel S. (Edmonds WA), Metal radionuclide labeled proteins for diagnosis and therapy.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhanced transmembrane transport of exogenous molecules.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Tweedle Michael F. ; Gaughan Glen T.,GBX ; Hagan James J., Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs.
Tweedle Michael F. (Princeton NJ) Gaughan Glen T. (Oxford GB2) Hagan James J. (Holmdel NJ), Method for imaging mammalian tissue using 1-substituted- 4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and anal.
Tweedle Michael F. ; Gaughan Glen T.,GB2 ; Hagan James J., Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analo.
Tweedle Michael F. (Hightstown NJ) Gaughan Glen T. (Oxford NJ GB2) Hagan James J. (Holmdel NJ), Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analog.
Skold Carl N. (Mountain View CA) Shanafelt Armen B. (Redwood City CA) Ghazarossian Vartan (Menlo Park CA) Ullman Edwin F. (Atherton CA), Method for immunochromatographic analysis.
Griffiths Gary L. (Morristown NJ) Hansen Hans J. (Mystic Island NJ) Karacay Habibe (Matawan NJ), Modified radioantibody fragments for reduced renal uptake.
Katti Kattesh V. (Columbia MO) Volkert Wynn A. (Columbia MO) Ketring Alan R. (Columbia MO) Singh Prahlad R. (Columbia MO), New multifunctional ligands for potential use in the design therapeutic or diagnostic radiopharmaceutical imaging agents.
Dunn T. Jeffrey (Cedar Mill MO) Nosco Dennis (Florissant MO) Woulfe Steven (Hazelwood MO) Dean Richard (Downingtown PA) Wester Dennis (Lynwood WA), Novel TC-99M complexes.
Hansen Hans J. (Mystic Island NJ) Leung Shui-on (Madison NJ) Shevitz Jerry (Livingston NJ) Griffiths Gary L. (Morristown NJ) Govindan Seregulam V. (Summit NJ), Preparation and use of immunoconjugates.
Papahadjopoulos Demetrios ; Hong Keelung ; Zheng Weiwen, Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery.
Lyle Leon R. (Webster Groves MO) Kunkel Steven L. (Ann Arbor MI) Strieter Robert M. (Ann Arbor MI), Radiolabeled neutrophil activating peptides for imaging.
Butterfield Dennis E. ; Fujii Dennis K. ; Ladd David L. ; Snow Robert A. ; Tan Julia S. ; Toner John L., Segmented chelating polymers as imaging and therapeutic agents.
Boguslaski Robert C. (Elkhart IN) Burd John F. (Elkhart IN) Carrico Robert J. (Elkhart IN), Specific binding assay employing an enzyme-cleavable substrate as label.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.